Phase 1 Study Assessing the Safety and Tolerability of CTX-4430

Ascending single oral doses of CTX-4430 will be administered to subjects in 6 cohorts on day 1. Following a 14-day washout, subjects in two of the six cohorts will cross-over, fed a high fat diet and administered different single oral doses of CTX-4430

excipient blended with CTX-4430 in capsules

Single oral doses of placebo will be administered to subjects in 6 cohorts on day 1. Following a 14-day washout, subjects in two of the six cohorts will cross over, fed a high fat diet and administered single oral doses of placebo

Ascending repeat doses of CTX-4430 will be administered orally, once-daily, to subjects in 4 cohorts on days 1-14.

Repeat doses of placebo will be administered orally, once-daily, to subjects in 4 cohorts on days 1-14.

excipient blended with CTX-4430